Dubodencel Fast Track: treatment of glioblastoma and pancreatic cancer
Learn how dubodencel received its third Fast Track status from the FDA for treating glioblastoma, pancreatic cancer, and melanoma. Analysis of the dual-loading dendritic cell platform and prospects for patients.
